Current Role of Protective Agents in Cancer Treatment

ONCOLOGY

Volumn 11, Issue 4, 1997, Pages 505-516

  Schlichter, Lynn M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; BLEOMYCIN SULFATE; CISPLATIN; CYTOPROTECTANT; DIETHYLDITHIOCARBAMIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; METHOTREXATE; MITOMYCIN; MITOMYCIN C; RAZOXANE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SODIUM THIOSULFATE; TRIMETREXATE; UNCLASSIFIED DRUG;

BONE MARROW RESCUE; CANCER PREVENTION; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOCALCEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; TREATMENT INDICATION; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONY-STIMULATING FACTORS; COMBINED MODALITY THERAPY; CYTOTOXINS; HUMANS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS;

EID: 0030756555     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. DeVita VT, Hubbard CM, Longo DL: The chemotherapy of lymphomas: Lookmg back, moving forward - The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 47:5810-5824, 1987.
2. Bonadonna G, Vatagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 332:901-906, 1995.
3. Hryniuk WM: The importance of dose intensity in the outcome of chemotherapy, in DeVita V, Hellman S, Rosenberg S (eds): Important Advances in Oncology, pp 121-141. Philadelphia, JB Lippincott, 1988.
4. Myers CE, McGuire WP, Liss RH, et al: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197, 165-167, 1977.
5. Hay J, Shahzeidi S, Laurent G: Mechanisms of bleomycin-induced lung damage. Arch Toxicol 65:81-94, 1991.
6. McDonnell TJ, Meyn RE, Robertson LE: Implication of apoptotic cell death regulation in cancer therapy Semin Cancer Biol 6:53-60, 1995.
7. Moreira LF, Naomoto Y, Hamada M, et al: Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy. Anticancer Res 15:639-644, 1995.
8. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32:39-47, 1994
9. Keith FJ, Bradbury DA, Zhu YM, et al: Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-c. Leukemia 9:131-138, 1995.
10. Gasparini G, Barbareschi M, Doglioni C, et al: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1:189-198, 1995
11. Dole M, Nunez G, Merchant AK, et al: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54:3253-3259, 1994
12. Kerr JF, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Ccmcer 73(8):2013-2026, 1994.
13. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471-4478, 1995.
14. Milas L, Stephens LC, Meyn RE: Relation of apoptosis to cancer therapy. In Vivo 8:665-673, 1994.
15. Anand S, Verma H, Kumar L, et al: Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and adriamycin. Cancer Lett 88:101-105, 1995.
16. Li X, Gong J, Feldman E, et al: Apoptotic cell death during treatment of leukemias. Leak Lymphoma 13 (suppl 1) 65-70, 1994.
17. 1 expression, cytostasis and apop- tosis in human breast cancer cells Br J Cancer 72:1441-1446, 1995.
18. Frankfurt OS, Sugarbaker EV, Robb JA, et al: Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett 97:149-154, 1995.
19. Havrilesky LJ, Elbendary A, Hurteau JA, et al: Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 85:1007-1010, 1995.
20. Skeel RT, Lachant NA: Handbook of Cancer Chemotherapy, 3rd ed, pp 147-148. Boston, Little Brown, 1995.
21. Walther MM: Cystitis, in DeVita VT, Bellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 4th ed, pp 2358-2362. Philadelphia, JB Lippincott, 1993.
22. Schuchter LM, Glick J: The current status of WR-2721 (amifostine): A chemotherapy and radiation therapy protector. Biologic Therapy of Cancer 3:1-10, 1993.
23. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by 3-2-(3-aminopropylamino) ethyl-phosphorothioic acid. Cancer Res 40:1519-1524, 1980.
24. Schuchter LM, Luginbuhl WE, Meropol NJ: The current status of toxicity protectants in cancer therapy. Semin Oncol 19:742, 1992.
25. Coleman N, Bump E, Kramer R: Chemical modifiers of cancer treatment. J Clin Oncol 6:709-733, 1988.
26. Yuhas JM, Spellman JM, Jordan SW: Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 42:574-585, 1980.
27. Yuhas JM, Spellman JM, Culo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3:211-216, 1980.
28. Shaw I., Glover D, Turrisi A, et al: Pharmacokinetics of WR-2721. Pharmacol Ther 39:195-201, 1988
29. Smoluk GD, Fahey RC, Ward JF: Interaction of glutathione and other low molecular weight thiols with DNA: Evidence for counter ion condensation and coion depletion near DNA. Radiat Res 114:3-10, 1988.
30. Grdina DJ, Shigametsu N, Dale P, et al: Thiol and disulfide metabolites of the radiation protector and chemopreventive agent WR 2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 16:767-774, 1995.
31. Milas L, Hunter N, Stephens CL, Peters LJ: Inhibition of radiation carcinogenesis by S-2-3 aminopropylamino-ethylphosphorothioic acid Cancer Res 44:5567-5569, 1984.
32. Grdina DJ, Nagy B, Sigdestad CP: Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Pharm Ther 39:21-25, 1988.
33. Woloschak GE, Paunesku T, Chang-Liu CM, Grdina DJ. Expression of thymidine kinase messenger RNA and a related transcript is modulated by radioprotector WR-1065. Cancer Res 55:4788-4792, 1995.
34. Glover D, Glick J, Weiler C, et al: Phase I trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 10:1781-1784, 1984.
35. Kligerman M, Glover D, Turrisi A, et al: Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 10:1773-1776, 1984
36. Glover D, Grabelsky S, Fox K, et al: Clinical trials of WR 2721 and cis-platinum Int J Radiat Oncol Biol Phys 16, 1201-1204, 1989.
37. Mollman JE, Glover DJ, Hogan WM, et al: Cisplatin neuropathy: Risk factors, prognosis, and protection by WR-2721. Cancer 61:2192-2195, 1988.
38. Al-Sarraf M, Flelcher WS, Oishi N, et al: Cisplalin hydration with and without mannitol in refractory disseminated malignant melanoma: A Southwest Oncology Group Study. Cancer Treat Rep 66:31-35, 1982.
39. Glover D, Click J, Weiler C, et al: WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Oncol 4(4):584-588, 1986.
40. Kemp G, Rose P, Luram J, et al: Amifostine pretreatment for protection against cyclophosphamide- and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996.
41. Di Paola R, Rodriguez R, Recio A, et al: A phase I study of amifostine and paclitaxel in patients with advanced malignancies. Am Med Soc Clin Oncol (15)488, 1966.
42. Liu T, Liu Y, He S, et al: Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 69:2820-2825, 1992.
43. Shpall EJ, Stemmer SM, Hami L, et al: Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide C purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83(11):3132-3137, 1994.
44. Douay L, Mu C, Giarratana M-C, et al: Amifostine improves the antileukemic theapeutic index of mafosfamide: Implication for bone marrow purging. Blood 88:2849-2855, 1995.
45. Glover D, Riley L, Carmichael K, et al: Hypocalcemia and inhibition of parathyroid hormone secretion after administration of amifostine (a radioprotective and chemoprotective agent). N Engl J Med 309:117-1141, 1983.
46. Budd GT, Ganapathi R, Bauer L, et al: Phase I study of WR-2721 and carboplatin. Eur J Cancer 29A:1122-1127, 1993
47. Green MD, Alderton P, Sobol MM, et al: ICRF-187 (ADR-529) cardioprotection against anthracycline-inducedcardiotoxicity: clinical and preclinical studies, in Muggia FM (ed): New Drugs, Concepts, and Results in Cancer Chemotherapy pp 101-117, Boston, Kluwer Academic Publishers, 1992.
48. Koning J, Palmer P, Franks CR, et al: Cardioxane-ICRF-187: Towards anticancer drug specificity through selective toxicity reduction. Cancer Treat 18:1-19, 1991.
49. Hasinoff BB: The iron (III) and copper (II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) Agents Actions 29:374-381, 1990
50. Herman EH, Mhatre RM, Chadwick DP: Modification of some of the toxic effects of daunorubicin (NSC082, 151) by pretreatment with the antineoplastic agent ICRF-159. Toxicol Appl Pharmacol 27:517-526, 1974.
51. Speyer JL, Green MD, Zelenluch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992.
52. Bokkel-Huinink WW, Schreuder JE, Dub- bleman R, et al: ICRF-187 protects against doxorubicin-induced cardiomyopathy. Ann Oncol 3 (suppl 1):A221, 1992.
53. Schoenike SE, Dana WJ: Ifosfamide and mesna. Clin Pharm 9:179-191, 1990.
54. Mohrmann M, Kupper S, Schonfield B, et al: Ifosfamide and mesna: effects of the Na/M exchanger activity in renal epithelial cells in culture (LLC-PK1). Ren Physiol Biochem 18(3): 118-127, 1995.
55. Gabrilove J, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988.
56. Pettengell R, Gumey H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992.
57. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A(3):319-324, 1993.
58. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991.
59. Taylor KMcD, Jannagath S, Spitzer G, et al: Recombinant human granulocyte colony stimulating factor shortens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 7 1791-1799, 1989.
60. Lieschke GJ, Ramenghi U, O'Connor MP, et al: Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol 82:589-595, 1992.
61. Bunn PA, Crowley J, Hazuka M, et al. The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group. Proc Am Soc Clin Oncol 11:292, 1992.
62. Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant human GM-CSF after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773-1778, 1991
63. Antman KH: GM-CSF in marrow transplant Eur J Cancer 29A (suppl 3):S2-S6, 1993.
64. Gerhartz HH, Engelhard M, Meusers P, et al: Randomized, double-blind, placebo-controlled phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodskin's lymphomas. Blood 82:2329-2339, 1993
65. Gianni AM, Bregni M, Siena S, et al. Recombinant human GM-CSF reduces hemato- logic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 8(5):768-778, 1990.
66. Meropol NJ, Miller IL, Korn EL, et al: Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 84:1201-1203, 1992.
67. Momin F, Kraut M, Lattin P, et al: Thrombocytopema in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 11:294, 1992.
68. Yau JC, Neidhart JA, Triozzi P, et al: Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide. etoposide, and cisplatin. Am J Hematol 51:289-295, 1996.
69. Stoller RG, Handi KR, Jacobs SA, et al: Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630-634, 1977
70. Schiller JH, Storer B, Berlin J, et al: Amifostine, cisplatin and vinblastine in metastatic non-small-cell lung cancer. A report of high response rates and prolonged survival J Clin Oncol 14:1913-1921, 1996.
71. Ishida R, Hamatake M, Wasserman RA, et al: DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55(11):2299-2303, 1995.
72. Scambia G, Della Bitta R, Benedetti Panici P, et al: Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells. Gynecol Oncol 57(1): 16-22, 1995.
73. Rhomberg W, Eiter H, Hergan K, et al: Inoperable recurrent rectal cancer: Results of a prospective trial with radiation therapy and razoxane. Int J Radiat Oncol Biol Phys 30(2):419-425, 1994.
74. Goodman TL, McKenna LM, Li JT. Clinical pharmacology and efficacy of mesna given to outpatients treated with ifosfamide for solid tumors. Proc Am Soc Clin Oncol 11 272, 1992.
75. Katz S, Epelman S, Annelli A, et al: Mesna-based uroprotection: sustained and simplified schedule - results of a randomized trial. Proc Am Soc Clin Oncol 11:1351, 1992.
76. Chi K-H, Chen C-M, Chan W-K, et al: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 13:2620-2628, 1995.
77. Du XX, Doezschuck CM, Orazi A, et al: A bone marrow stromal-derived growth factor, in- terleukin 11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1:33-37, 1994.
78. Sonis ST, Lindqvist L, Van Vugt AA, et al: Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor b3. Cancer Res 54:1135-1138, 1994.
79. Motoji T, Watanabe M, Uzumaki H, et al: Granulocyte colony-stimulating factor (G-CSF) receptors on acute myeloblastic leukaemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay. Br J Haematol 77:54-59, 1991.
80. Rowe JM, Anderson J, Mazza JJ, et al: A randomized placebo controlled phase III study of granulocyte-macrophage colony-stimulating factors in adult patients (> 55-70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490) AML Blood 86(2):457-462, 1995.
81. Estey E, Thall PF, Kantarjian H, et al: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 79:2246-2255, 1992.
82. Schuster MW, Larson RA, Thompson JA, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): Results of multi-center, randomized, controlled trial (abstract). Blood 76(suppl 1):318a, 1990.
83. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS) (abstract) Blood 82(suppl 1):196a, 1993.
84. Dedhar S, Gaboury L, Galloway P, et al. Human granulocyte macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhematopoictic origin. Proc Natl Acad Sci USA 9253-9257, 1988.
85. de Vries EGE, Biesnu B, Willemse PMB, et al: A double blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 51:116-122, 1991
86. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hematopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys 22:773-779, 1992.
87. MacVittie TJ, Brandenburg R, Farese AM, et al: Enhanced recovery from supralethal radiation exposure using combined modality WR-2721 plus recombinant human (rh) G-CSF. Proc Am Assoc Cancer Res 33:505, 1992.